3rd Quarter - Report

PURDUE PHARMA, LP for PURDUE PHARMA LP

Period 3rd Quarter 2018 Filed Oct 22, 2018 Signed by BURT E. ROSEN

Official filing
Firm
PURDUE PHARMA, LP
Client
PURDUE PHARMA LP
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Alcohol and Drug Abuse ALC

-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act

LobbyistCovered position, as disclosed
WILLIAM R NORDWIND New —
BURT E ROSEN —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 5582 (115th), H.R. 6 (115th)

Health Issues HCR

-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act

LobbyistCovered position, as disclosed
WILLIAM R NORDWIND New —
BURT E ROSEN —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 6 (115th), H.R. 5582 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.